Tuesday, January 31, 2023
Charles River announced the acquisition of SAMDI Tech. The acquisition is the culmination of an exclusive partnership between the companies started in 2018.
The acquisition of SAMDI Tech’s cutting-edge, high-throughput screening technology further strengthens Charles River’s drug discovery capabilities and enhances unique ability to better serve as an integrated partner to support clients’ early-stage research.
The combination of this end-to-end portfolio and industry-leading scientific expertise with SAMDI Tech’s innovative MS technology and expertise in assay solutions will significantly accelerate and augment clients’ discovery efforts by measuring biochemical activities and hit identification for virtually any small molecule drug target.
This acquisition provides Charles River’s clients a seamless access to the premier, label-free HTS MS platform to create a comprehensive, industry-leading library of drug discovery solutions and creates new business opportunities for Charles River family.
